Clinical Trial Update: High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating high-dose melphalan with peripheral stem cell transplantation in patients with primary systemic amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis

Drugs mentioned

• Peripheral stem cell transplantation
• high-dose melphalan (melphalan)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED